Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.
Health Canada Approves Upadacitinib to Treat Adults with PsA
Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.
New Insights into CD8+ T Cells & Lupus
A recent study demonstrated that exposure to type I interferon contributes to the pathogenesis of SLE via the metabolic rewiring of CD8+ T cells, which promotes cell death.
Advocates for Arthritis 2021 Applications Now Open
The ACR is accepting applications for this year’s Advocates for Arthritis event, which will be held virtually on Sept. 27–28. This annual event brings together patients and rheumatology professionals to advocate for our subspecialty on Capitol Hill. Applications are also open for the Advocacy 101 program, which provides advocacy training for ACR/ARP members. Apply today…
Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis
In an efficacy and safety study of guselkumab, patients with active psoriatic arthritis taking guselkumab showed continued skin clearance and joint symptom relief, as well as statistically significant inhibition of joint damage, after two years.
COVID-19 Puts Latino Patients with Rheumatic Disease at Risk of a Disease Flare
In their new study, Fike et al. found Latino patients with rheumatic diseases have a higher rate of COVID-19 than the general Latino population. Obesity is a risk factor for COVID-19, and COVID-19 is a risk factor for rheumatic disease flare.
Untangling the Diagnosis & Management of GCA
Vision loss, implications of treatment and more—Sarah Mackie, BMBCh, PhD, MRCP, discussed the latest research on the evaluation and management of giant cell arteritis.
Grinding Away: An Overview of Progress in the Treatment & Management of Osteoarthritis
Convex-walking shoes, dietary supplements, advancements in nerve growth factor inhibitors and more—Xavier Chevalier gave an overview and new insights into treatments for osteoarthritis.
Insight into the Biosimilar Prescribing Habits of Rheumatologists
The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.
Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis
Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.
- « Previous Page
- 1
- …
- 142
- 143
- 144
- 145
- 146
- …
- 816
- Next Page »